Floatz logo

Thalidomide

Nutritional Deficiency Disease

Chinese University of Hong KongSmall moleculePhase 4 / ApprovedDormant
BB
65/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
50/ 100
Competitive Position
95/ 100

Competitive context

4 Active assets in the Nutritional Deficiency Disease cohort.

Asset / SponsorPhaseRating
Intralipid
Johane Allard
Phase 4BB
Retrovir
International Maternal Pediatric Adolescent AIDS Clinical Trials Group
Phase 4BB
Methoxy Polyethylene Glycol-Epoetin Beta
Taipei Veterans General Hospital, Taiwan
Phase 4BB
Guanfacine
Maimonides Medical Center
Phase 4BB
Lamivudine
International Maternal Pediatric Adolescent AIDS Clinical Trials Group
Phase 4BB

View all 31 →

Same molecule, other indications

Thalidomide is also rated in:

central nervous system neoplasmActive
BB
Indicative · Phase 2
70 / 100
View asset →
plasma cell myelomaActive
BB
Indicative · Phase 4
68 / 100
View asset →
uveal melanomaDormant
BB
Indicative · Phase 2
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →